US 11,752,242 B2
Medical devices, systems, and methods utilizing antithrombin-heparin composition
Attilio Difiore, West Jordan, UT (US); Leslie Roy Berry, Burlington (CA); and Anthony Kam Chuen Chan, Ancaster (CA)
Assigned to ATH Therapeutics Inc., Alexandria, VA (US)
Appl. No. 15/735,306
Filed by ATH Therapeutics Inc., Alexandria, VA (US); and Attilio Difiore, West Jordan, UT (US)
PCT Filed Jun. 10, 2016, PCT No. PCT/US2016/036855
§ 371(c)(1), (2) Date Dec. 11, 2017,
PCT Pub. No. WO2016/201202, PCT Pub. Date Dec. 15, 2016.
Claims priority of provisional application 62/174,308, filed on Jun. 11, 2015.
Prior Publication US 2018/0177924 A1, Jun. 28, 2018
Int. Cl. A61L 33/00 (2006.01); A61L 29/16 (2006.01); A61L 31/16 (2006.01); A61K 47/55 (2017.01); A61K 47/61 (2017.01); A61L 27/54 (2006.01); A61K 47/64 (2017.01); A61P 27/02 (2006.01); A61P 7/02 (2006.01); A61K 9/00 (2006.01); A61K 31/727 (2006.01); A61K 38/17 (2006.01)
CPC A61L 33/0011 (2013.01) [A61K 9/0048 (2013.01); A61K 31/727 (2013.01); A61K 38/1709 (2013.01); A61K 47/55 (2017.08); A61K 47/61 (2017.08); A61K 47/64 (2017.08); A61L 27/54 (2013.01); A61L 29/16 (2013.01); A61L 31/16 (2013.01); A61P 7/02 (2018.01); A61P 27/02 (2018.01); A61L 2300/42 (2013.01); A61L 2420/02 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A medical device having reduced thrombogenicity, the medical device comprising a polymeric surface having a compound bonded to the polymeric surface of the medical device, wherein the compound includes an antithrombin-heparin conjugate,
wherein at least 98% of heparin chains in the antithrombin-heparin conjugate have a molecular weight greater than 5,000 Daltons,
wherein the antithrombin-heperain conjugate is conjugated at the aldose terminus aldehyde on the heparin and a lysyl or N-terminal amino group on antithrombin.